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Summary
DNA-damage checkpoints maintain genomic integrity
by mediating a cell-cycle delay in response to geno-
toxic stress or stalled replication forks. In response
todamage, the checkpoint kinaseATRphosphorylates
and activates its effector kinase Chk1 in a process
that critically depends on Claspin [1]. However, it is
not knownhowexactly this kinase cascade is silenced.
Here we demonstrate that the abundance of Claspin
is regulated through proteasomal degradation. In re-
sponse to DNA damage, Claspin is transiently stabi-
lized, and its expression depends on Chk1 kinase
activity. In addition, we show that Claspin is degraded
upon mitotic entry, a process that depends on the b-
TrCP-SCF ubiquitin ligase and Polo-like kinase-1 (Plk1).
We demonstrate that Claspin interacts with both
b-TrCP and Plk1 and that inactivation of these com-
ponents or the b-TrCP recognition motif in Claspin
prevents its mitotic degradation. Interestingly, expres-
sionof anondegradableClaspinmutant inhibits recov-
ery from a DNA-damage-induced checkpoint arrest.
Thus, we conclude that Claspin levels are tightly regu-
lated, both during unperturbed cell cycles and after
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chusetts 021329.DNA damage. Moreover, our data demonstrate that
the degradation of Claspin at the onset of mitosis is
an essential step for the recovery of a cell from a
DNA-damage-induced cell-cycle arrest.
Results and Discussion
Claspin Turnover Is Regulated during the Cell Cycle
and in Response to DNA Damage
Activation of Chk1 by the DNA-damage-responsive
checkpoint kinase ATR critically depends on the pres-
ence of Claspin, which acts as an adaptor protein to
link Chk1 and ATR [1, 2]. Interestingly, Claspin levels
were shown to oscillate during the cell cycle, suggesting
that the checkpoint response is cell-cycle dependent
[2]. To investigate this dependence, we analyzed Clas-
pin levels at different stages during the cell cycle
(Figure 1A). Claspin levels are high during S and early
G2 phase, whereas Claspin levels sharply decrease as
cells accumulate in the G2 and M phases (Figure 1A).
Indeed, we could show by immunofluorescence that
Claspin is virtually absent in mitotic cells (Figure 1B).
We further confirmed downregulation of Claspin in mi-
totic cells by using the microtubule-destabilizing drug
nocodazole, which blocks cell-cycle progression in
prometaphase of mitosis (Figure 1C). Moreover, Claspin
levels rapidly increased upon release from the nocoda-
zole block, at time points when cells progressively en-
tered G1 and S phase (Figure S1A in the Supplemental
Data available online). Finally, cells arrested in G2 after
treatment with the DNA-damaging agent camptothecin
displayed high levels of Claspin (Figure S1B). These
results indicate that Claspin is stabilized in cells that
are prevented from entering mitosis and suggest that
Claspin is degraded at mitotic onset, possibly pre-
cluding further activation of Chk1 by ATR.
We also analyzed the levels of Claspin after different
genotoxic insults. We observed an increase in Claspin
levels shortly after UV treatment and a decrease at later
time points (Figure 1D). These fluctuations in Claspin
levels were also observed with other types of DNA-dam-
aging agents, including hydroxyurea (causing stalled
replication forks), etoposide, and camptothecin (the
last two causing both single- and double-strand DNA
breaks) (Figure 1D and data not shown). Thus, in addi-
tion to the observed decrease of Claspin at mitotic entry,
we also found upregulation of Claspin levels in response
to genotoxic stress.
The rapid increase in Claspin levels after DNA dam-
age suggested that this could not be due to transcrip-
tional regulation, and we tested whether altered protea-
somal degradation is involved. Indeed, treating U2OS
cells with the proteasome inhibitor MG132 resulted in
an increase of Claspin levels, up to the maximal level
of expression that is seen in response to DNA damage
(Figures 2A and 2B). Interestingly, addition of MG132
to damaged cells could not elicit a further increase in
Claspin expression (Figure 2B) but did prevent the
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1951Figure 1. Claspin Regulation during the Cell Cycle and after DNA Damage
(A) U2OS cells were synchronized at the G1/S transition by double thymidine block, and cells were collected at different times after release for
flow cytometry and western blot analysis.
(B) U2OS cells were analyzed by immunofluorescence using DAPI, anti-Claspin and anti-phospho-HistoneH3 as a mitotic marker. Arrowhead
points at a mitotic cell.
(C) U2OS cells were left untreated or arrested with nocodazole for 18h and whole cell extracts (WCE) were prepared for analysis of Claspin
expression. Cyclin E was used as an S-phase marker.
(D) U2OS cells were treated with UV light (40 J/m2) or with 0.5 mM camptothecin (CPT) for 1 hr. Cells were collected at the indicated time points for
analysis of Claspin expression.reduction normally seen in Claspin levels at the later
stages of the damage response (data not shown). More-
over, we found that the reduction seen for Claspin
expression in mitotic cells was blocked by MG132,
indicating that this reduction is due to enhanced
processing of Claspin by the proteasome (Figure 2C).
Altogether, these data demonstrate that Claspin is con-
tinuously turned over by the proteasome in undam-
aged cells, that it becomes transiently stabilized in re-
sponse to DNA damage, and that its turnover is even
further enhanced at mitotic entry. Consistent with this,
we could detect a smear of higher molecular weight
than Claspin in cells cotransfected with HA-tagged
Claspin and His-tagged ubiquitin, indicating that Clas-
pin is indeed poly-ubiquitinated (Figure 2D). Further-
more, we could demonstrate poly-ubiquitination of
endogenous Claspin in cells treated with proteasome
inhibitors (Figure 2E). Notably, Claspin ubiquitination
was significantly enhanced in mitotic cells (Figure S2),
whereas overall levels of HA-Claspin were considerably
lower in mitotic cells than in the asynchronous cultures,
consistent with the notion that Claspin turnover is in-
creased upon entry into mitosis.
Chk1 and Polo-like Kinase-1 Exert antagonistic
effects on Claspin turnover
Several examples of regulated proteasomal degradation
by means of substrate phosphorylation exist in theliterature, and because both Chk1 and Plx1 are known
to interact with Claspin [1, 3], we tested whether Chk1
and Polo-like kinase-1 (Plk1) can affect Claspin turn-
over. Indeed, whereas expression of wild-type Chk1
did not destabilize Claspin, overexpression of a kinase-
dead version of Chk1 resulted in destabilization of
Claspin protein levels (Figure 3A). Consistent with these
observations, downregulation of Chk1 by siRNA also
resulted in a decrease in Claspin levels (Figure 3B).
These data confirm recent findings by Chini et al. [4]
but furthermore show that this Chk1-mediated stabiliza-
tion of Claspin requires Chk1 kinase activity.
We next set out to determine whether Plk1, the human
Plx1 homolog, was also able to modulate Claspin levels.
Plk1 is expressed in G2 and mitosis but only becomes
activated as cells enter mitosis, which is also when Clas-
pin levels drop. Indeed, we could show that overexpres-
sion of Plk1 resulted in a downregulation of Claspin (Fig-
ure 3C). This effect depends on the catalytic activity of
Plk1; expression of a kinase-defective mutant of Plk1
could not cause downregulation of Claspin (Figure 3C).
In addition, by using GST fusions comprising differ-
ent regions of Claspin [2], we were able to show that
Plk1 can interact with the C-terminal half of Claspin
(Figure S3A), consistent with findings of Yoo et al. in
Xenopus [3]. We were able to confirm this interaction fur-
ther by coimmunoprecipitation of Myc-tagged kinase-
dead Plk1 with endogenous Claspin in vivo and vice
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1952Figure 2. Claspin Protein Levels Are Regu-
lated via Proteasome-Dependent Degrada-
tion
(A) U2OS cells were treated with MG132 for
the indicated times before Western-blot anal-
ysis with the indicated antibodies.
(B) U2OS cells were incubated with MG132
for 3 hr before treatment with UV light (40
J/m2). Cells were collected 1 hr after UV treat-
ment for analysis of Claspin expression.
(C) Claspin expression in U2OS cells treated
with nocodazole for 8 hr in the presence or
absence of MG132. Untreated cells were
taken along as a control.
(D) HEK 293T cells were transfected with indi-
cated plasmids. After 36 hr, cells were lysed
and extracts were incubated with Ni-NTA
beads. After washing, the resin was analyzed
for Claspin ubiquitination.
(E) U2OS cells were incubated for 3 hr in the
presence of MG132 before lysis. Extracts
were used for immunoprecipitations with
Claspin or control IgG antibodies. Analysis
was done by Western blotting with antibodies
against Claspin and ubiquitin.versa (Figure 3D and data not shown). This interaction of
Plk1 with Claspin is mediated through the conserved
Polo-box domain (PBD), as demonstrated by pull-
down experiments with a GST fusion of the PBD of
Plk1 (Figure 3E).
Using RNA-interference to deplete Plk1, we assessed
whether Plk1 is required for the degradation of Claspin
at mitotic onset. Indeed, depletion of Plk1 in HeLa and
U2OS cells was able to prevent the degradation of Clas-
pin in mitosis (Figure 3F), indicating that Plk1 is essential
for mitotic Claspin degradation. Interestingly, whereas
control-transfected mitotic cells show loss of Claspin
during mitosis, no clear reduction in Claspin levels was
observed in Plk1-depleted mitotic cells (Figure S3B).
b-TrCP Targets Claspin for Degradation
The SCF (Skp1-Cullin-F-box-protein) ubiquitin ligase
complex is responsible for the degradation of multiple
proteins during mitotic onset. In particular, key mitotic-
entry regulators, such as Wee1 and Emi1 [5–7], are de-
graded by the b-TrCP-SCF complex in a Plk1-dependent
fashion. To test whether Claspin might also be degraded
by the b-TrCP-SCF complex, we downregulated b-TrCP1/2
by shRNA. Importantly, downregulation of b-TrCP1/2
resulted in elevation of Claspin protein levels during mi-
tosis (Figure 4A), and we could demonstrate an interac-
tion between Claspin, b -TrCP1/2 and Skp1 (Figure S4A
and data not shown). Interestingly, a DSGxxS motif
that is present in most SCF substrates [8] can be recog-
nized in a conserved region in the N terminus of Claspin
(Figure S4B). To investigate whether this DSGxxS motif
is required for Claspin targeting for proteasomal degra-
dation, we generated point mutants in which the two
essential serines were replaced by alanines (Claspin
S30/34A). Strikingly, the S30/34A mutant displayed areduced affinity for b-TrCP1/2 as compared to wt-Claspin
(Figure 4B), and disruption of the recognition motif
abolished Claspin degradation in mitotic cells (Figure 4C).
Together, these results show the significant role for the
b-TrCP1/2-SCF complex in Claspin degradation at mi-
totic onset. Also, they suggest that Plk1 might act at mul-
tiple points to promote checkpoint recovery. We have
previously demonstrated that Plk1 promotes proteaso-
mal degradation of the Cdk-inhibitory kinase Wee1 [7],
which acts at the bottom of the checkpoint signaling cas-
cade. Here we show that Plk1 is also involved in promot-
ing the degradation of Claspin. Similar to Wee1, Plk1 can
promote the proteasomal degradation of Claspin in a b-
TrCP1/2-dependent fashion. This degradation requires
the presence of a phosphodegron motif (DSGxxS), which
is also found in otherb-TrCP1/2 substrates, such as Emi1
[5, 6]. Presently, we do not know whether Plk1 directly
phosphorylates the serines in the phosphodegron motif
or whether Plk1-dependent degradation of Claspin by
the b-TrCP1/2-SCF complex occurs in a more complex
fashion, as was shown for Wee1 [9].
Claspin Degradation Is Required
for Checkpoint Recovery
The downregulation of Claspin levels at mitotic entry
might act to prevent Chk1 activation during mitosis. In-
deed, we found that Chk1 can be activated in mitotic
cells expressing the nondegradable S30/34A mutant of
Claspin (Figure 4D), indicating that the degradation of
Claspin is required to inactivate the checkpoint in mito-
sis. Similarly, degradation of Claspin might be a way to
decrease Chk1 activity during recovery from a check-
point arrest. To test this latter hypothesis, we arrested
U2OS cells in G2 with a DNA-damaging agent and then
treated them with caffeine to induce checkpoint
Plk1-Dependent Degradation of Claspin
1953Figure 3. Chk1 and Plk1 Both Regulate Claspin Levels
(A) HEK 293T cells were transfected with wild-type or kinase-dead versions of Flag-Chk1. WCE were analyzed by Western blot for Claspin
expression.
(B) U2OS cells were transfected with control (Luciferase) or Chk1 siRNA for 72 hr. WCE were analyzed by Western blotting.
(C) 293T cells were transfected with Myc-tagged versions of wild-type or kinase-dead Plk1. After 36 hr, WCE were made and analyzed.
(D) Immunocomplexes isolated with control or Myc antibodies from U2OS cells expressing Myc-kd-Plk1 were analyzed by Western blotting for
associated Claspin.
(E) U2OS cells were transfected with HA-Claspin and treated for 16 hr with taxol. Alternatively, cells were pretreated with doxorubicin (0.5 mM) for
1 hr. WCE were subsequently incubated with recombinant GST-PBD. WCE and pull-down fractions were analyzed by Western blot.
(F) U2OS or HeLa cells were transfected with the pSuper or pSuper-Plk1 plasmids and subsequently arrested with thymidine for 24 hr. S-phase
(2 hr after release) and mitotic shake-off fractions (18 hr after release, in the presence of nocodazole) were collected. WCE were analyzed by
Western blot.recovery. Caffeine inhibits the checkpoint kinases ATM
and ATR and silences the checkpoint, allowing cells to
recover from the arrest [10]. Indeed, whereas Chk1 phos-
phorylation is lost upon caffeine treatment in control
cells, Plk1 depletion resulted in less-efficient Chk1 de-
phosphorylation after checkpoint silencing (Figure 4E).
As expected, the status of Chk1 phosphorylation com-
pletely matched the presence or absence of Claspin
(Figure 4E). To confirm that Claspin degradation is a
key event in checkpoint recovery, we next assessed
the effects of expressing the nondegradable Claspin mu-
tant S30/34A. Expression of this mutant significantly
lowered the extent of checkpoint recovery in response
to different types of DNA damage. When caffeine wasused to silence the G2 DNA-damage checkpoint induced
by doxorubicin or camptothecin, a clear decrease in
checkpoint recovery was visible in cells expressing non-
degradable Claspin (Figure 4F). These results indicate
that degradation of Claspin indeed is an important
requirement during checkpoint recovery induced by
caffeine treatment. We next investigated spontaneous
checkpoint recovery by using hydroxyurea. Eighteen
hours after a 1 hr pulse with 10 mM hydroxyurea, most
cells had recovered, as evidenced by a high mitotic index
(Figure 4F). However, cells expressing the nondegrad-
able Claspin displayed a significant decrease in check-
point recovery (Figure 4F). Together, these results dem-
onstrate that the Plk1-dependent process of Claspin
Current Biology
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(A) U2OS cells were transfected with pSuper-GFP or pSuper-b-TrCP1/2 in combination with pBabePuro. Twelve hours after transfection, cells
were incubated with puromycin for 24 hr. Cells were then left untreated or incubated with nocodazole for 16 hr. Mitotic cells were collected by
gentle shake-off, and WCE were prepared and analyzed by Western blot.
(B) HEK 293T cells were transfected with Flag-b-TrCP2 together with HA-wt-Claspin or HA-S30/34A-Claspin. Immunoprecipitations for Flag were
analyzed by Western blot with HA and Flag antibodies.
(C) U2OS cells were transfected with HA-wt-Claspin or HA-S30/34A-Claspin. Cells were treated with nocodazole for 12 hr, then, mitotic cells were
collected by gentle shake-off, and WCE were prepared and analyzed by Western blot.
(D) U2OS cells were left untransfected (left panel) or were transfected with either HA-wt-Claspin or HA-S30/34A-Claspin (right panel). Mitotic
cells were obtained by treatment of the cells with nocodazole followed by mitotic shake off. Where indicated, cells were treated with UV
light (20 J/m2), and WCE were made 90 min later. Claspin and HA antibodies were used for detection of endogenous and exogenous Claspin,
respectively.
(E) U2OS cells were transfected with pSuper or pSuper-Plk1 and were synchronized with a 24 hr thymidine block. Eight hours after release, cells
were treated for 1 hr with doxorubicin (0.5 mM) or left untreated. Subsequently, nocodazole was added. After 16 hr, all doxorubicin-treated
cells were arrested in G2. These cells were left untreated or were treated with 5 mM caffeine for 8 hr. WCE were prepared and analyzed by
Western blotting with the indicated antibodies (left panel). In parallel, DNA content and MPM2 positivity was assessed by flow cytometry
(right panel).
(F) U2OS cells were transfected with HA-wt-Claspin or HA-S30/34A-Claspin and treated as for Figure 4E. In addition, similar experiments were
performed with camptothecin and hydroxyurea. Subsequently, cells were fixed and stained for MPM2. Relative mitotic indices are shown
(mitotic indices of HA-wt-Claspin were put to 100%). Recovery after hydroxyurea was assessed in the absence of caffeine.
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1955degradation is a key event in allowing recovery after an
arrest by the DNA-damage checkpoint.
Taken together, our observations indicate that the
degradation of Claspin serves to silence the DNA-dam-
age checkpoint at mitotic entry. Moreover, we find that
expression of nondegradable Claspin inhibits mitotic
entry after checkpoint recovery. This effect is seen in
cultures that have been arrested in G2 via a variety of
DNA damaging agents and that are subsequently in-
duced to enter mitosis by treatment with caffeine. In ad-
dition, the effect of nondegradable Claspin on recovery
is even more pronounced in cultures that are allowed
to recover spontaneously from a hydroxyurea-induced
S-phase arrest, representing a physiological condition
of checkpoint recovery. In contrast, expression of non-
degradable Claspin has no effect on mitotic entry in an
unperturbed cell cycle, indicating that Claspin degrada-
tion is not required per se for mitotic entry under all
conditions. Importantly, expression of a nondegradable
Claspin behaves in a similar way as Plk1 depletion,
which we previously showed to lead to a stringent
block in checkpoint recovery while failing to block mi-
totic entry in cells that did not activate the G2 DNA-
damage checkpoint [10]. Thus, Plk1-induced Claspin
degradation appears to positively regulate checkpoint
recovery, and interference in this pathway severely
limits the capacity of a cell to recover from genotoxic
stress.
These results are in good agreement with data from
yeast, where the budding yeast polo-homolog Cdc5 is
required for the inactivation of the DNA checkpoint
kinase Rad53 [11]. Moreover, Polo-like kinase appears
to function both in checkpoint adaptation, as was shown
in Xenopus [3], and in checkpoint recovery, as we dem-
onstrate here in human cells. Nonetheless, there is
a clear difference in the mechanism by which Claspin
function is controlled in these two different organisms.
Plx1-mediated phosphorylation in Xenopus leads to dis-
placement of Claspin from the chromatin, without con-
comitant Claspin degradation [3]. In contrast, in human
cells Plk1-mediated phosphorylation causes destruc-
tion of Claspin, pointing to a more rigorous, irreversible
control mechanism. Interestingly, such a fundamental
difference is not without precedent; others have shown
that interference with the function of Orc1 occurs
through its displacement from chromatin in Xenopus,
whereas this is mediated via protein destruction in hu-
man cells [12]. Also, although binding of Plx1 to xClaspin
requires ATR-dependent phosphorylation, it is likely that
the priming of Claspin for binding to Plk1 in human cells
involves alternative kinases [13]. The identity of these
kinases and the mechanism by which Plk1 is reactivated
after genotoxic stress and allowed to trigger downregu-
lation of Claspin remain the most interesting questions
to resolve because they will help us understand how
a cell switches from a checkpoint-arrested state to a
state of active recovery. Clearly, our data show that
the action of Plk1 during recovery is not restricted to
Wee1 but that it also regulates a core checkpoint com-
ponent that acts at the top of the signaling cascade. In
light of our data, one could even speculate that mere
activation of Plk1 in DNA-damaged cells might be suffi-
cient to silence the checkpoint and promote checkpoint
adaptation.Supplemental Data
Supplemental Data include four figures and Experimental Proce-
dures and can be found online at: http://www.current-biology.
com/cgi/content/full/16/19/1950/DC1/.
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